皮肤黑色素瘤患者血清蛋白酶活化受体-1 (PAR-1)水平的临床意义

BBA clinical Pub Date : 2016-06-01 DOI:10.1016/j.bbacli.2016.04.001

Faruk Tas, Elif Bilgin, Senem Karabulut, Kayhan Erturk, Derya Duranyildiz

{"title":"皮肤黑色素瘤患者血清蛋白酶活化受体-1 (PAR-1)水平的临床意义","authors":"Faruk Tas, Elif Bilgin, Senem Karabulut, Kayhan Erturk, Derya Duranyildiz","doi":"10.1016/j.bbacli.2016.04.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Protease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of PAR-1in cutaneous melanoma patients.</p></div><div><h3>Methods</h3><p>A total of 60 patients with a pathologically confirmed diagnosis of cutaneous melanoma were enrolled into this study. Serum PAR-1concentrations were determined by the solid-phase sandwich ELISA method.</p></div><div><h3>Results</h3><p>No significant difference in serum PAR-1 levels between melanoma patients and healthy controls was found (p=0.07). The known clinical variables including age of patient, gender, site of lesion, histology, stage of disease, serum LDH levels and chemotherapy responsiveness were not correlated with serum PAR-1 concentrations (p>0.05). Likewise, serum PAR-1 concentration had also no prognostic role on survival (p=0.41).</p></div><div><h3>Conclusion</h3><p>Serum levels of PAR-1 have no diagnostic, predictive and prognostic roles in cutaneous melanoma patients.</p></div><div><h3>General significance</h3><p>Measurement of PAR-1 in serum is not a clinical significance in cutaneous melanoma patients.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.04.001","citationCount":"3","resultStr":"{\"title\":\"Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma\",\"authors\":\"Faruk Tas, Elif Bilgin, Senem Karabulut, Kayhan Erturk, Derya Duranyildiz\",\"doi\":\"10.1016/j.bbacli.2016.04.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Protease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of PAR-1in cutaneous melanoma patients.</p></div><div><h3>Methods</h3><p>A total of 60 patients with a pathologically confirmed diagnosis of cutaneous melanoma were enrolled into this study. Serum PAR-1concentrations were determined by the solid-phase sandwich ELISA method.</p></div><div><h3>Results</h3><p>No significant difference in serum PAR-1 levels between melanoma patients and healthy controls was found (p=0.07). The known clinical variables including age of patient, gender, site of lesion, histology, stage of disease, serum LDH levels and chemotherapy responsiveness were not correlated with serum PAR-1 concentrations (p>0.05). Likewise, serum PAR-1 concentration had also no prognostic role on survival (p=0.41).</p></div><div><h3>Conclusion</h3><p>Serum levels of PAR-1 have no diagnostic, predictive and prognostic roles in cutaneous melanoma patients.</p></div><div><h3>General significance</h3><p>Measurement of PAR-1 in serum is not a clinical significance in cutaneous melanoma patients.</p></div>\",\"PeriodicalId\":72344,\"journal\":{\"name\":\"BBA clinical\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.04.001\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BBA clinical\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2214647416300150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BBA clinical","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214647416300150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

摘要

蛋白酶活化受体-1 (PAR-1)在多种恶性肿瘤的发病机制中起着重要作用，其表达也强烈影响肿瘤患者的预后。本研究的目的是确定皮肤黑色素瘤患者血清par -1水平的临床意义。方法共纳入60例经病理证实的皮肤黑色素瘤患者。采用固相夹心ELISA法测定血清par -1浓度。结果黑色素瘤患者血清PAR-1水平与健康对照组无显著差异(p = 0.07)。已知临床变量包括患者年龄、性别、病变部位、组织学、疾病分期、血清LDH水平和化疗反应性与血清PAR-1浓度无相关性(p >0.05)。同样，血清PAR-1浓度对生存也没有预后作用(p = 0.41)。结论血清PAR-1水平在皮肤黑色素瘤患者中无诊断、预测和预后作用。皮肤黑色素瘤患者血清PAR-1检测无临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma

Background

Protease-Activated Receptor-1 (PAR-1) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of PAR-1in cutaneous melanoma patients.

Methods

A total of 60 patients with a pathologically confirmed diagnosis of cutaneous melanoma were enrolled into this study. Serum PAR-1concentrations were determined by the solid-phase sandwich ELISA method.

Results

No significant difference in serum PAR-1 levels between melanoma patients and healthy controls was found (p = 0.07). The known clinical variables including age of patient, gender, site of lesion, histology, stage of disease, serum LDH levels and chemotherapy responsiveness were not correlated with serum PAR-1 concentrations (p > 0.05). Likewise, serum PAR-1 concentration had also no prognostic role on survival (p = 0.41).